SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Gong appoints Liron Shtraichman as Chief R&D Officer

Sequoia raises $10 billion as it dismantles parts of its global operation

Former Amdocs CEO disclosed $22.5 million in share sales before stock plunged, filings show

Nice says Actimize sale process remains ongoing, offers no update on reported $2 billion Brookfield deal

Buzz

Most popular

Daily

Weekly

1

Google expands buyouts while Wiz acquisition helps lift headcount to record levels

2

Nice to lay off 500 employees as it struggles to navigate the AI transition

3

Amdocs shares plunge 44% as T-Mobile dispute threatens revenue

4

Israeli startup Explorium shuts down after raising more than $127 million

5

From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits

UroGen

5 stories about UroGen

אריה בלדגרין דוקטור מנכ"ל ו ממייסדי קייט פארמה

”Exits are not a Strategy. I Never put up a ‘For Sale’ Sign”

23.05.20|Sophie Shulman and Golan Hazani

Arie Belldegrun, chairman of UroGen Pharma, talks about catching Covid-19 and gaining FDA approval in the midst of a global pandemic

Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen

The two companies will collaborate on the research of a “therapeutic area of mutual interest”

Sustained Drug Release Company UroGen Aiming to Raise $150 Million on Nasdaq

24.01.19|Lilach Baumer

Goldman Sachs & Co. LLC, JP Morgan, and Jefferies are the joint bookrunners for the offering

Sustained Drug Release Company UroGen Submits New Drug Application to FDA

12.07.18|Amir Rosenbaum

Kite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections

Allergan Partners with Urine Incontinence Treatment Company

08.11.17|Lilach Baumer

Allergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen